Saniona AB

SANION · Nasdaq Stockholm · Healthcare

9.60SEK +1.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: −17.9%

Performance

1 month

−19.0%

1 year

−17.9%

3 years, per year

+22.1%

5 years, per year

−3.1%

Largest fall, 3 years

−91.5%

Below the peak now

−78.2%

Volatility, 1 year

56.4%

Return with dividends reinvested.

Key figures

P/E

7.0

P/B

2.3

Dividend yield

0.0%

Return on equity

+33.5%

Net margin

+43.2%

Market value

132 m USD

Quality, value and trend

Where Saniona stands against every Nordic stock today. 100 is best.

Quality99

Profitability and a sound balance sheet over time. Better than 99% of Nordic stocks.

Value61

The price measured against earnings, assets and cash flow. Better than 61% of Nordic stocks.

Trend16

The price development over the past year. Better than 16% of Nordic stocks.

Combined64

Quality, value and trend together. Better than 64% of Nordic stocks.

About Saniona

Saniona AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 44 employees.

Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis